Nutriband Updates Shareholders on Key Milestones and New Directors Appointment
Nutriband has provided an update to shareholders on the key milestones and discussions from this years Annual Shareholders Meeting. Addition of Two New Directors: Allesandro Puddu and Viorica Carlig added as two new directors. 2025 Aversa Fentanyl Development Summary: Strengthened collaboration with Kindeva through an exclusive product development partnership; Granted patent protecting its Aversa abuse deterrent platform technology in Macao; Completed commercial manufacturing process scale-up with partner Kindeva for Aversa Fentanyl; Issued new US patent which further expands Nutriband's intellectual property protection in the United States; Held Type C meeting with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for Aversa Fentanyl; Filed a new provisional patent application with the U.S. Patent and Trademark Office covering improved aversive formulations and coating application methods; Initiated development of the worldwide commercial brand name and visual identity for Aversa Fentanyl with Brand Institute. 2026 Aversa Fentanyl Focus on Development Towards NDA Filing: File nonprovisional patent application to potentially extend patent protection of Aversa technology-based products to 2046; Manufacture clinical supplies for the Human Abuse Liability clinical trial; File Investigational New Drug application with the US FDA; Initiate Human Abuse Liability clinical study. EarthVision Bio Purchase of Pocono Pharma: The full purchase price and closing for the proposed sale of our Pocono subsidiary has not been received as of the shareholder meeting on Jan 24, 2026. However, the Company is collecting on the agreed nonrefundable $10,000 USD weekly penalty and has so far collected $30,000 USD of payments to extend the closing date.
Trade with 70% Backtested Accuracy
Analyst Views on NTRB
No data
About NTRB
About the author
Nutriband Annual Meeting Update: New Directors and Product Developments
- New Director Appointments: At the Annual Shareholders Meeting on January 24, 2026, Nutriband appointed two new directors, Alessandro Puddu and Viorica Carlig, with Puddu bringing over 10 years of experience in audit and financial reporting, while Carlig adds extensive leadership and compliance expertise, enhancing the company's governance and strategic execution capabilities.
- AVERSA™ FENTANYL Progress: Strengthened collaboration with Kindeva for the exclusive product development of AVERSA™ FENTANYL, where both parties share development costs in exchange for milestone payments, which is expected to accelerate product commercialization and enhance market competitiveness.
- Patent Protection Expansion: Nutriband secured a patent for its AVERSA™ abuse deterrent platform technology in Macao, further solidifying its intellectual property and providing legal protection for global market expansion.
- Shareholder Complaint and Penalties: The company filed a complaint with FINRA to investigate suspected naked short selling and has collected $30,000 in penalties to extend the closing date, which will help protect shareholder interests and bolster market confidence.
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Shareholder Value Enhancement: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M will add $5M to its bottom line without diluting existing shareholders, demonstrating the company's commitment to shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, thereby enhancing shareholder returns and loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying the groundwork for future commercialization, showcasing its technological edge in drug safety.
- Market Expansion: Nutriband's inclusion in four major indexes, including Russell Microcap and Russell 3000E, enhances its market visibility and investment appeal, potentially attracting more investors to its future growth prospects.
